酚妥拉明联合苯巴比妥治疗肝炎后高胆红素血症的临床观察

To study the therapeutic effect and safety of phentolamine-mesilate combined with phenobarbital for treating posthepatitic hyperbilirubinemia.86 patients with posthepatitic hyperbilirubinemia were randomly divided into treated group (n=42) and control group (n=34) .The treated group was treated with 10mg phentolaminemesilate, once daily by intravenous drip, and 30mg phenobarbital, three times daily by orally taken.The control group was given 20ml potassium magnesium aspartate and 20mg vitamin K1, once daily by intravenous drip.The treated course for both groups was 4 weeks.Before and after treatment, the changes of liver function of the two groups were detected respectively.The results showed that total effective rate of the treatment group was 77.3% (34/44) , and that of the control group 52.5% (22/42) .There was significantly different on total effective rate between the two groups (P<0.01) .No remarkable adverse effects in the treatment group had been observed.It suggested that phentolamine-mesilate combined with phenobarbital had good clinical efficacy and was a safe agent for treating posthepatitic hyperbilirubinemia.